Drug intelligence / Profile preview

human papillomavirus type 45 L1 capsid protein antigen

Development stage
Approved
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Human papillomavirus type 45 L1 capsid protein antigen is a recombinant viral-like particle (VLP) derived from the major capsid (L1) protein of HPV type 45. It is produced in Saccharomyces cerevisiae and self-assembles into VLPs that mimic the structure of native HPV but lack viral DNA, making them non-infectious. This antigen is a component of the Gardasil 9 vaccine, which provides immunization against diseases caused by HPV type 45—including cervical cancer and other anogenital cancers—by inducing neutralizing antibodies that prevent infection with this virus subtype[1][5][7]. The primary mechanism is to stimulate an immune response against HPV-45 through presentation of the L1 VLPs.

Brand names
Gardasil 9Gardasil9Gardasil-9
Other names
L1 proteinL-1 proteinL 1 proteinHuman papillomavirus type 45 vaccinerecombinant human papillomavirus type 45 L1 protein
02

Targets

BCR (Immunoglobulin G B Cell Receptor)HPV45 L1

Beyond the preview

Go deeper on human papillomavirus type 45 L1 capsid protein antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human papillomavirus type 45 L1 capsid protein antigen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call